News & Media

ABILIFY MYCITE (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE System includes: ABILIFY MYCITE, the MYCITE® Patch (wearable sensor); the MYCITE APP (a smartphone application); and web-based portals for healthcare providers and caregivers1 The

Tolvaptan has been studied in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in a clinical trial program which included more than 3,165 trial participants exposed to at least one dose of tolvaptan across 18 trials[i]ADPKD is a progressive disease leading to kidney failure, diagnosed in 100,000 to 150,000 people in the U.S.[ii]April 2018 is the anticipated completion timing

REPRISE trial presented as a late breaking abstract at American Society of Nephrology (ASN) Kidney Week 2017Tolvaptan reduced the rate of decline of kidney function by 35 percent over a 12-month period, compared to placebo, in patients with ADPKDADPKD, the most common type of polycystic kidney disease, is a progressive disease leading to kidney failure, diagnosed in 100,000 to 150,000 people

Tokyo, Japan and Valby, Denmark - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the two companies will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type. The trial is expected to commence during the first half of 2018.   The decision to initiate a third trial